Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
12.76
+0.75 (6.24%)
At close: Jan 30, 2025, 4:00 PM
12.75
-0.01 (-0.08%)
After-hours: Jan 30, 2025, 6:04 PM EST
Dogwood Therapeutics Employees
Dogwood Therapeutics had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,431,256
Market Cap
17.00M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
DWTX News
- 4 months ago - Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - GlobeNewsWire
- 6 months ago - Virios Therapeutics Announces Second Quarter 2024 Financial Results - GlobeNewsWire
- 6 months ago - Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - GlobeNewsWire
- 6 months ago - Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center - GlobeNewsWire
- 9 months ago - Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - GlobeNewsWire
- 9 months ago - Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - GlobeNewsWire
- 9 months ago - Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - GlobeNewsWire
- 9 months ago - Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript - Seeking Alpha